about
Interstitial fluid flow and drug delivery in vascularized tumors: a computational modelIntravital microscopy for evaluating tumor perfusion of nanoparticles exposed to non-invasive radiofrequency electric fieldsThe tumor microenvironment and strategies to improve drug distributionEffect of transcatheter intraarterial therapies on the distribution of Doxorubicin in liver cancer in a rabbit modelExtracellularly activatable nanocarriers for drug delivery to tumors.Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targetingTreating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound.The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.Simultaneous detection of intracellular target and off-target binding of small molecule cancer drugs at nanomolar concentrations.Understanding Drug Resistance in Breast Cancer with Mathematical OncologyNon-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopyTuning payload delivery in tumour cylindroids using gold nanoparticles.Evaluation of therapeutics in three-dimensional cell culture systems by MALDI imaging mass spectrometry.Strategies for advancing cancer nanomedicine.Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancerRecovery of intrinsic fluorescence from single-point interstitial measurements for quantification of doxorubicin concentrationTrg-deficient Salmonella colonize quiescent tumor regions by exclusively penetrating or proliferating.ABC transporters: unvalidated therapeutic targets in cancer and the CNSIntratumoral drug delivery with nanoparticulate carriers.Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagyUtilizing native fluorescence imaging, modeling and simulation to examine pharmacokinetics and therapeutic regimen of a novel anticancer prodrug.Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment.Cancer cell spheroids as a model to evaluate chemotherapy protocols.Fluorescence properties of doxorubicin in PBS buffer and PVA films.Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumorsNanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities.Microcirculatory fraction (MCF(I)) as a potential imaging marker for tumor heterogeneity in breast cancer.The role of tumor tissue architecture in treatment penetration and efficacy: an integrative study.Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistanceTargeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapyPrediction of drug response in breast cancer using integrative experimental/computational modeling.Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing.Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation.Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells.A theoretical quantitative model for evolution of cancer chemotherapy resistanceHeterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
P2860
Q27310300-67343267-834F-4EFB-8243-50FA6511871EQ27319974-FD4AB22A-9065-48AC-B3B4-79996C6EE4A8Q28384148-1AE0BDE0-5A4B-4F3B-966A-B6FA83BA3806Q28534244-D7054697-6FFC-4D58-8ADC-919C0E348FEBQ30401826-321B1208-15C8-43CA-AAEA-ADA44F8701E0Q30456053-53463449-ABF2-4032-83BB-F1E24B60CB93Q30469830-8810E3CD-9EDD-44C1-A875-1874DC1CBA54Q33508944-F4C074EE-329E-4F1A-812E-D2637F3C0F8AQ33621763-56132597-8977-41C4-9C05-027A7CD8778AQ33690336-96F4A238-E17E-4AAE-A40C-8E6B001E74DDQ33708056-471179A6-DC48-4F69-9EDA-9822C76CA99FQ33895572-20AD0D1B-DCE3-4A61-BF84-677E9010431CQ33988838-7DECA877-7519-470D-B633-453C7BA70180Q33995719-E8BE18E9-44C7-4CB2-94A7-294332C0C1B7Q34701798-97672C2E-D5BC-4461-A246-18B9FCC6B67FQ34987662-E3EDB0F4-7998-43A2-B2F0-F9B6AE1E6291Q35020097-2291A56E-BD27-4C7F-BC17-9A0BF7CFE25BQ35056738-510F64AA-7179-49AB-BD56-520D81CAB671Q35091415-F5F7C45D-6A3F-4DF4-BF7F-4E45E6A52879Q35176800-8CADF2D2-8B1F-431C-900A-2FBFBF03D19FQ35622211-6C443B1F-3496-46D2-B91B-E7510CA37018Q35678695-5B6742D1-06B4-4C76-B810-4C5EBBEF16C9Q36085539-43B93367-5958-4B54-A5D6-49B6ED404982Q36248902-34BFC10E-390B-4EFF-9B02-D316A207524FQ36312156-AAFC52F1-A8BF-419F-A62E-AEC741AC27F7Q36340797-A654EC89-CBBC-4F4B-96FD-BAE2349C0969Q36412928-0DD7B76E-DA97-4E2F-AB6B-E0757A24B36FQ36454792-EFD74692-02ED-4D55-BE9E-4FF597ADC1A9Q36803827-1F480D77-247F-4984-A691-B7DA93E757ABQ36821142-C65B4DD6-1D9F-46F8-A948-13A20F6DFAABQ36833440-CCA52129-B786-4FF5-8C18-595BA4FEFC55Q36907239-D700911E-CD67-4B5E-808E-9FE9C375E245Q36923104-372F2A3F-7BEB-425F-81B9-D99F495A0B73Q36952188-26382918-B2F8-4161-A832-C75C922EF33CQ37288570-BD47C607-136B-4BA9-BD3D-E4E89858AC4DQ37381491-D6BCFD73-7DA8-4ABB-85C6-F9F9A919606DQ37433585-4DA46DA4-78BC-426F-9B19-FF73BC0A1A55Q38865261-65C6BF07-872E-495B-AA69-E838CF8E80DBQ40516956-0EB5F6A9-99D6-44EC-B557-BFAA1B8189B0Q41276800-10963BB5-52AB-490F-BAE7-D64ED3A9A9E4
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Doxorubicin gradients in human breast cancer.
@ast
Doxorubicin gradients in human breast cancer.
@en
type
label
Doxorubicin gradients in human breast cancer.
@ast
Doxorubicin gradients in human breast cancer.
@en
prefLabel
Doxorubicin gradients in human breast cancer.
@ast
Doxorubicin gradients in human breast cancer.
@en
P2093
P1476
Doxorubicin gradients in human breast cancer
@en
P2093
Lankelma J
van Diest PJ
van der Valk P
P304
P407
P577
1999-07-01T00:00:00Z